NCT04990531 (DECRYPT) is a NA clinical trial of Low-field magnetic resonance imaging in Sars-CoV-2 Infection, sponsored by University of Erlangen-Nürnberg Medical School.

Who is sponsoring NCT04990531?

NCT04990531 is sponsored by University of Erlangen-Nürnberg Medical School.

What drugs are being tested in NCT04990531?

Interventions in NCT04990531: Low-field magnetic resonance imaging, Blood sample.

What condition does NCT04990531 study?

NCT04990531 studies Sars-CoV-2 Infection, Lung Fibrosis, Covid19.

Is NCT04990531 still recruiting?

NCT04990531 is currently status unknown. Last updated 5 January 2022.

Last reviewed 2022-01-05 · How we verify

NCT04990531: DECRYPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low-field Magnetic Resonance Imaging of Pediatric COVID-19

Status unknown NA Last updated 5 January 2022

What this trial tests

NA trial testing Low-field magnetic resonance imaging in Sars-CoV-2 Infection in 68 participants. Status unknown.

Timeline

9 August 2021

Primary endpoint
29 December 2021

1 January 2022

Quick facts

Lead sponsor	University of Erlangen-Nürnberg Medical School
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	68
Start date	9 August 2021
Primary completion	29 December 2021
Estimated completion	1 January 2022
Sites	1 location across Germany

Drugs / interventions tested

Low-field magnetic resonance imaging
Blood sample — full drug profile →

Conditions studied

Sars-CoV-2 Infection — all drugs for Sars-CoV-2 Infection →
Lung Fibrosis — all drugs for Lung Fibrosis →
Covid19 — all drugs for Covid19 →

Sponsor

University of Erlangen-Nürnberg Medical School

Who can join

Adults 5 to 18, any sex, with Sars-CoV-2 Infection or Lung Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. They predominantly cause mild colds but can sometimes cause severe pneumonia. The long-term consequences are still largely unexplained and misunderstood, especially in children and adolescents. The aim of this study is to assess the frequency of pulmonary skeletal changes in pediatric and adolescent patients using low-field magnetic resonance imaging (LF-MRI) in the setting of proven past SARS-CoV-2 infection.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Pulmonary Dysfunction after Pediatric COVID-19.
Heiss R, Tan L, Schmidt S, Regensburger AP, et al · · 2023 · cited 58× · PMID 36125379 · DOI 10.1148/radiol.221250
Longitudinal functional lung imaging in children with Post-COVID-19 syndrome.
Kraus C, Tan L, Hinsen M, Schmidt S, et al · · 2026 · PMID 41618035 · DOI 10.1186/s40348-025-00216-x
Abstracts des Kongresses für Kinder- und Jugendmedizin 2022
· 2022
Persisting pulmonary dysfunction in pediatric post-acute Covid-19
Heiss R, Wagner A, Tan L, Schmidt S, et al · · 2022 · DOI 10.1101/2022.02.21.22270909

Verify or expand the search:

Other trials of Low-field magnetic resonance imaging

Trials testing the same drug.

NCT06093334 — Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD · NA · completed
NCT05445531 — Low-field Magnetic Resonance Imaging in Pediatric Post Covid-19 · NA · unknown

Other recruiting trials for Sars-CoV-2 Infection

Currently open trials in the same condition.

NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
NCT04964115 — Post Acute Sequelae of COVID-19 · active not recruiting

Other University of Erlangen-Nürnberg Medical School trials

Trials by the same sponsor.

NCT06969820 — Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT · not yet recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07352540 — Single vs Triple Hyaluronic Acid in Knee Osteoarthritis · Phase 2, PHASE3 · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT07121985 — Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré S · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04990531 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Erlangen-Nürnberg Medical School
Last refreshed: 5 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04990531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing